HCG18是一种潜在的致病因子,也是阿尔茨海默病的诊断生物标志物
Pingting Chen1, Genru Li2, Lingyan Cheng3
1Department of Neurology, Wenling TCM Hospital Affiliated to Zhejiang Chinese Medical University, Zhejiang, 317500, China.
Neurochemical research
|February 7, 2026
概括
长非编码RNA HCG18在阿尔茨海默病 (AD) 患者中显示血清水平升高,作为潜在的生物标志物. HCG18通过菌miR-425-3p加剧神经元损伤,这表明了AD的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 在早期诊断和治疗方面存在重大挑战.
- 长非编码RNA (lncRNAs) 正在成为神经退行性疾病的关键参与者.
- 确定AD的新生物标志物和治疗点是迫切需要的.
研究的目的:
- 为了研究 lncRNA HCG18 在阿尔茨海默病中的诊断价值.
- 为了阐明HCG18在神经元损伤中的分子机制.
- 探索HCG18/miR-425-3p轴作为AD治疗点的潜力.
主要方法:
- 在83名AD患者和83名健康对照中使用qRT-PCR量化血清HCG18表达.
- 脑脊液 (CSF) 的AD生物标志物被ELISA分析.
- 在HT22细胞中使用Aβ1-42诱导的神经损伤模型来研究HCG18的功能及其与miR-425-3p的相互作用.
主要成果:
- 艾滋病患者的血清HCG18水平明显高于对照组 (P < 0.001),诊断准确度高 (AUC = 0.889).
- HCG18表达与CSF Aβ1-42和MMSE分数负相关,与t-tau和p-tau181.1.正相关.
- 通过减少细胞亡和氧化应激,HCG18的敲击保护了Aβ1-42诱导的神经元损伤,机械地作为miR-425-3p的海绵.
结论:
- 血清HCG18是阿尔茨海默病诊断的有前途的非侵入性生物标志物.
- HCG18通过miR-425-3p海绵化机制加剧神经元损伤,从而促进AD的发病.
- 准HCG18/miR-425-3p通路为阿尔茨海默病提供了潜在的治疗策略.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...


